The Fly | CRSP

Over a week ago

Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO

+32

Jun 11, 2:02 PM

Crispr Therapeutics assumed at Equal Weight from Underweight at Morgan Stanley

CRSP

Jun 11, 6:16 AM

FDA issues draft guidance to help accelerated cell, gene therapies for patients

+24

Jun 2, 9:40 AM

Crispr Therapeutics price target raised by $6 at Bernstein, here's why

CRSP

May 13, 6:28 AM

FDA Commissioner Marty Makary resigns

+17

May 12, 1:58 PM

Crispr Therapeutics price target raised by $2 at Evercore ISI

CRSP

May 11, 8:04 AM

Crispr Therapeutics price target raised by $2 at Citi

CRSP

May 6, 7:04 AM

Crispr Therapeutics price target lowered by $3 at BofA, here's why

CRSP

May 5, 8:40 AM

Crispr Therapeutics reports Q1 EPS ($1.28), consensus ($1.23)

CRSP

May 4, 4:45 PM

Crispr Therapeutics price target raised by $5 at Piper Sandler, here's why

CRSP

Mar 17, 6:54 AM

Cathie Wood's ARK Investment buys 113K shares of Crispr Therapeutics today

CRSP

Mar 12, 8:54 PM

Crispr Therapeutics prices upsized convertible senior notes offering

CRSP

Mar 11, 7:12 AM

Cathie Wood's ARK Investment buys 281K shares of Crispr Therapeutics today

CRSP

Mar 10, 9:03 PM

What You Missed On Wall Street On Tuesday

+22

Mar 10, 4:19 PM

Crispr Therapeutics falls -9.2%

CRSP

Mar 10, 12:01 PM

Midday Fly By: HP Enterprise reports Q1 beat, BioNTech announces new company

+22

Mar 10, 11:59 AM

Crispr Therapeutics announces proposed convertible senior notes offering

CRSP

Mar 10, 7:15 AM

Crispr Therapeutics rumor highlighted in Betaville blog

CRSP

Feb 26, 10:39 AM

Crispr Therapeutics price target raised by $1 at Morgan Stanley, here's why

Feb 17, 8:33 AM

Crispr Therapeutics price target lowered by $2 at JPMorgan, here's why

CRSP

Feb 16, 7:55 AM

Crispr Therapeutics price target raised by $3 at Citi, here's why

CRSP

Feb 16, 7:46 AM

Crispr Therapeutics price target raised by $2 at Chardan, here's why

CRSP

Feb 14, 6:41 AM

Crispr Therapeutics price target raised by $2 at Needham, here's why

CRSP

Feb 13, 9:04 AM

Crispr Therapeutics price target raised by $12 at Evercore ISI, here's why

Feb 13, 9:02 AM

Crispr Therapeutics price target raised by $5 at TD Cowen, here's why

CRSP

Feb 13, 8:46 AM

Pioneering Market Entry with Approved Therapy: Crispr Therapeutics holds the distinction of being part of the team that brought the world's first CRISPR-based gene editing therapy, Casgevy, to market, establishing an early lead in the therapeutic application of this technology.

Robust Foundational IP Portfolio: The company possesses a strong intellectual property portfolio, including licenses to foundational CRISPR/Cas9 patents, which provides a significant barrier to entry for competitors and protects its core technology.

Validated Technology Platform: The regulatory approval and commercialization of Casgevy for sickle cell disease and beta-thalassemia validate the safety and efficacy of their CRISPR gene editing platform, de-risking future pipeline assets.

Clinical Trial Success Risk: CRSP's lead product candidates, like Exa-cel, must demonstrate safety and efficacy in ongoing and future clinical trials to gain regulatory approval, and these trials are inherently uncertain and can fail at any stage.

Regulatory Approval Risk: CRSP's gene-editing therapies require extensive and lengthy regulatory approval from agencies such as the FDA and EMA, a process that is costly, uncertain, and may result in delays or outright denial.

Competition Risk: The gene therapy and rare disease markets are highly competitive, with numerous companies developing competing technologies and therapies that could prove more effective, safer, or commercially viable than CRSP's offerings.